TW202202501A - 結晶ret抑制劑 - Google Patents

結晶ret抑制劑 Download PDF

Info

Publication number
TW202202501A
TW202202501A TW110112512A TW110112512A TW202202501A TW 202202501 A TW202202501 A TW 202202501A TW 110112512 A TW110112512 A TW 110112512A TW 110112512 A TW110112512 A TW 110112512A TW 202202501 A TW202202501 A TW 202202501A
Authority
TW
Taiwan
Prior art keywords
serpatinib
acid
slurry
water
cancer
Prior art date
Application number
TW110112512A
Other languages
English (en)
Chinese (zh)
Inventor
拉杰尼 米格蘭尼 巴德瓦杰
馬克 史帝芬 克爾
道格拉斯 帕頓 謝爾
傑瑞米 邁爾斯 梅里特
喬 戈登 賽爾伯
謝克爾 克里希納 維斯瓦納特
Original Assignee
美商絡速藥業公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商絡速藥業公司 filed Critical 美商絡速藥業公司
Publication of TW202202501A publication Critical patent/TW202202501A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110112512A 2020-04-17 2021-04-07 結晶ret抑制劑 TW202202501A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US63/011,701 2020-04-17
US202163151354P 2021-02-19 2021-02-19
US63/151,354 2021-02-19

Publications (1)

Publication Number Publication Date
TW202202501A true TW202202501A (zh) 2022-01-16

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112512A TW202202501A (zh) 2020-04-17 2021-04-07 結晶ret抑制劑

Country Status (17)

Country Link
EP (1) EP4136090A1 (ja)
JP (1) JP2023522012A (ja)
KR (1) KR20230002706A (ja)
CN (1) CN115916791A (ja)
AU (1) AU2021255488B2 (ja)
BR (1) BR112022020446A2 (ja)
CA (1) CA3174316A1 (ja)
CL (1) CL2022002849A1 (ja)
CO (1) CO2022014882A2 (ja)
CR (1) CR20220520A (ja)
DO (1) DOP2022000221A (ja)
EC (1) ECSP22080982A (ja)
IL (1) IL297212A (ja)
MX (1) MX2022012952A (ja)
PE (1) PE20230388A1 (ja)
TW (1) TW202202501A (ja)
WO (1) WO2021211380A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
AU2022416156A1 (en) 2021-12-13 2024-05-30 Loxo Oncology, Inc. Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI812649B (zh) * 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US20210379056A1 (en) * 2018-09-30 2021-12-09 Applied Pharmaceutical Science, Inc. Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
KR20230002706A (ko) 2023-01-05
ECSP22080982A (es) 2023-01-31
CL2022002849A1 (es) 2023-06-16
AU2021255488A1 (en) 2022-11-10
IL297212A (en) 2022-12-01
JP2023522012A (ja) 2023-05-26
AU2021255488B2 (en) 2024-05-30
CA3174316A1 (en) 2021-10-21
CR20220520A (es) 2022-11-15
BR112022020446A2 (pt) 2022-11-29
DOP2022000221A (es) 2023-01-15
PE20230388A1 (es) 2023-03-06
MX2022012952A (es) 2023-01-11
EP4136090A1 (en) 2023-02-22
CN115916791A (zh) 2023-04-04
CO2022014882A2 (es) 2022-10-31
WO2021211380A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
JP2023506308A (ja) 複素環化合物およびその製造方法と使用
KR20160121544A (ko) N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n''-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
AU2021255488B2 (en) Crystalline RET inhibitor
WO2018045993A1 (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
EP3176173B1 (en) Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
TW202016114A (zh) 抑制ｃｄｋ４／６活性化合物的晶型及其應用
US20220372019A1 (en) Salts and solid state forms of plinabulin
US20230212193A1 (en) Crystalline ret inhibitor
CN113840605B (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途
TWI810338B (zh) Lta4h抑制劑的晶型
EP3849977B1 (en) Improved method for the manufacture of 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
TWI832608B (zh) Ret抑制劑之結晶形式及其製備
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
US20230373998A1 (en) Solid state forms of lorecivivint
WO2022033563A1 (zh) Jak抑制剂化合物及其用途
WO2024104354A1 (zh) 一种取代的哌嗪衍生物的晶体及其制备方法
CN111484489B (zh) 无定形的b-raf激酶二聚体抑制剂
TW202333672A (zh) Ｒｏｃｋ抑制劑的鹽及鹽的晶型、組合物和藥物用途
TW202311267A (zh) 咪唑烷酮類化合物的多晶型物、包含其的藥物組合物、其製備方法及其應用
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a